[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Spero Therapeutics Inc (SPRO)

Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 72,955
  • Shares Outstanding, K 57,901
  • Annual Sales, $ 66,800 K
  • Annual Income, $ 8,570 K
  • EBIT $ 14 M
  • EBITDA $ 14 M
  • 60-Month Beta 1.55
  • Price/Sales 1.10
  • Price/Cash Flow 8.28
  • Price/Book 1.38

Options Overview Details

View History
  • Implied Volatility 310.91% (+42.10%)
  • Historical Volatility 95.43%
  • IV Percentile 98%
  • IV Rank 51.65%
  • IV High 546.85% on 03/03/26
  • IV Low 58.84% on 05/04/26
  • Expected Move (DTE 13) 0.0000 (0.00%)
  • Put/Call Vol Ratio 2.33
  • Today's Volume 10
  • Volume Avg (30-Day) 403
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 7,545
  • Open Int (30-Day) 14,000
  • Expected Range 1.2600 to 1.2600

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.38
  • Growth Rate Est. (year over year) +262,994.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0800 +16.67%
on 07/24/26
2.3400 -46.15%
on 07/14/26
-0.9000 (-41.67%)
since 07/07/26
3-Month
1.0800 +16.67%
on 07/24/26
3.0800 -59.09%
on 05/27/26
-1.2500 (-49.80%)
since 05/07/26
52-Week
1.0800 +16.67%
on 07/24/26
3.0800 -59.09%
on 05/27/26
-0.9100 (-41.94%)
since 08/07/25

Most Recent Stories

More News
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology...

SPRO : 1.2600 (-0.79%)
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology...

SPRO : 1.2600 (-0.79%)
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

Dr. Zack brings more than 25 years of leadership in developing therapeutics for immune-mediated diseases Appointment strengthens Spero’s clinical leadership team as the Company advances SP001, a Phase...

SPRO : 1.2600 (-0.79%)
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil)...

KKR : 102.81 (-0.52%)
SPRO : 1.2600 (-0.79%)
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355) Innovent will receive an upfront...

SPRO : 1.2600 (-0.79%)
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment...

CMPS : 13.54 (-0.07%)
KLRA : 18.66 (-1.11%)
SPRO : 1.2600 (-0.79%)
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

First and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment 1 ...

SPRO : 1.2600 (-0.79%)
GSK.LN : 1,960.500 (+1.24%)
GSK : 52.96 (+1.51%)
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

First and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment i More than 3 million cases of cUTIs...

SPRO : 1.2600 (-0.79%)
GSK.LN : 1,960.500 (+1.24%)
GSK : 52.96 (+1.51%)
Compass Pathways Elects Kathleen Tregoning to Board of Directors

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to...

CMPS : 13.54 (-0.07%)
SPRO : 1.2600 (-0.79%)
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026 Spero maintains its...

SPRO : 1.2600 (-0.79%)

Business Summary

Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 1.3192
2nd Resistance Point 1.2993
1st Resistance Point 1.2797
Last Price 1.2600
1st Support Level 1.2402
2nd Support Level 1.2203
3rd Support Level 1.2007

See More

52-Week High 3.0800
Fibonacci 61.8% 2.3160
Fibonacci 50% 2.0800
Fibonacci 38.2% 1.8440
Last Price 1.2600
52-Week Low 1.0800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.